What’s Driving Fresh Interest in Mayne Pharma (ASX:MYX) Shares?

Highlights

• Mayne Pharma shares rose 4.52% to AUD 2.31 during the afternoon session on 5 June 2026.
• The company confirmed receipt of AUD 14.41 million from Cosette Pharmaceuticals.
• The payment covers legal costs, costs associated with the costs application, and interest.
• The recovery follows court orders issued by the Supreme Court of New South Wales on 29 May 2026.
• The latest payment represents another milestone in legal proceedings initiated by Mayne Pharma in June 2025.
• Cosette’s appeal against the October 2025 judgment was heard on 2 and 3 June 2026, with a decision currently reserved.

Mayne Pharma Group Ltd (ASX: MYX) shares climbed 4.52% to AUD 2.31 during the afternoon Trading session on 5 June 2026 after the company announced that it had received more than AUD 14.4 million from Cosette Pharmaceuticals under court orders. The update provided investors with another development in the ongoing legal dispute between the two companies, which has been progressing through Australian courts since 2025. Despite the day’s gain, Mayne Pharma shares remain down 52.86% over the past year.

About Mayne Pharma

Mayne Pharma is an Australian specialty pharmaceutical company focused on the development and commercialisation of medicines across several therapeutic areas. The company has established positions in dermatology and women’s health in the United States while also providing contract development and Manufacturing services to customers globally.

The Business has more than four decades of experience in pharmaceutical innovation, particularly in oral drug delivery technologies. Over the years, these technologies have been incorporated into multiple pharmaceutical products that continue to be marketed internationally. Through its commercial operations and development capabilities, the company aims to improve patient access to medicines while supporting pharmaceutical partners through manufacturing and development services.

Company Confirms Receipt of Court-Ordered Payment

In its latest market update, Mayne Pharma confirmed it had received a total payment of AUD 14,410,714.49 from Cosette Pharmaceuticals, Inc.

According to the company, the funds were paid in accordance with orders made by the Supreme Court of New South Wales on 29 May 2026. The payment includes recovery of legal costs incurred by Mayne Pharma during the proceedings, expenses associated with its application for costs, as well as accrued interest.

The receipt of these funds marks a notable step in the legal process that has unfolded over the past year. While the litigation itself remains ongoing due to an appeal process, the payment reflects the implementation of previously issued court orders relating to costs.

For investors, the announcement provides confirmation that the company has successfully recovered a substantial amount tied to the legal proceedings.

Background to the Cosette Dispute

The dispute between Mayne Pharma and Cosette dates back to June 2025, when Mayne Pharma commenced legal proceedings against Cosette.

The litigation arose following Cosette’s purported termination of a Scheme Implementation Deed that had been entered into by the two companies in February 2025.

A Scheme Implementation Deed is typically used to govern the terms and conditions of a proposed corporate transaction. Following the termination attempt, the disagreement moved into the legal arena, ultimately requiring court determination.

The case progressed through the Supreme Court of New South Wales, where the parties presented their respective arguments regarding the circumstances surrounding the termination and associated claims.

The proceedings became one of the more closely followed corporate legal matters involving the company, given the significance of the original transaction and its implications for both parties.

October 2025 Judgment Favoured Mayne Pharma

A major development in the dispute occurred in October 2025 when the Supreme Court of New South Wales delivered its judgment.

The Court ruled in favour of Mayne Pharma and dismissed all claims brought by Cosette. In addition to rejecting Cosette’s claims, the Court issued an adverse costs order against Cosette.

As a result of that order, Cosette became responsible for paying Mayne Pharma’s legal costs associated with the proceedings, either through agreement between the parties or through formal assessment.

The latest AUD 14.41 million payment announced by Mayne Pharma stems from these court-directed obligations.

The company described the payment as another successful milestone in the broader proceedings that began in 2025.

What the AUD 14.41 Million Payment Includes

The amount received by Mayne Pharma was not limited solely to legal fees.

The company stated that the payment comprises several components, including:

• Recovery of legal costs incurred during the proceedings.
• Costs associated with Mayne Pharma’s application for costs.
• Interest relating to the payment obligations.

Combined, these elements resulted in the total amount of AUD 14,410,714.49 received by the company.

The recovery of litigation-related costs can be meaningful from a corporate perspective, particularly when legal proceedings extend over lengthy periods and involve substantial professional expenses.

The latest payment effectively reimburses Mayne Pharma for a significant portion of the costs connected with the case, in line with the Court’s earlier orders.

Appeal Proceedings Remain Ongoing

While the company has now received the court-ordered payment, the broader legal process has not yet reached its final conclusion.

Mayne Pharma noted that Cosette appealed the October 2025 judgment in January 2026.

The appeal was subsequently heard by the Court of Appeal of the Supreme Court of New South Wales on 2 and 3 June 2026.

At this stage, the Court has reserved its decision, meaning the outcome of the appeal has not yet been delivered.

Reserved judgments are common in significant legal matters, providing the Court with additional time to consider submissions and evidence before issuing a ruling.

As a result, investors and Market Participants will continue monitoring future announcements regarding the appeal outcome and any potential implications arising from the decision.

Why Investors Appeared Encouraged by the Update

The market’s positive reaction on 5 June suggests investors viewed the announcement favourably.

The confirmation that Mayne Pharma has received more than AUD 14.4 million under court orders provides a tangible outcome from the proceedings and demonstrates progress in enforcing the Court’s earlier judgment.

The payment also represents a completed financial recovery rather than a prospective claim, with funds already received by the company.

In addition, the announcement reinforces the company’s position following the October 2025 court victory, even though the appeal process remains underway.

While legal disputes can often create uncertainty, the recovery of costs and interest under court orders may have contributed to improved market sentiment surrounding the update.

Legal Developments Continue to Shape the Narrative

For Mayne Pharma, the legal proceedings involving Cosette have remained an important corporate development over the past year.

The original dispute, subsequent court ruling, costs orders, and appeal process have collectively formed a significant part of the company’s recent corporate narrative.

The latest announcement does not provide any update on the likely timing of the appeal decision. However, it confirms that the costs component ordered by the Court has now translated into a substantial payment received by Mayne Pharma.

As the appeal remains under consideration, future developments will continue to be watched closely by shareholders and broader market participants.

What This Means for Investors

Mayne Pharma’s latest announcement confirms receipt of AUD 14.41 million from Cosette Pharmaceuticals under orders issued by the Supreme Court of New South Wales. The payment covers legal costs, associated costs applications and interest linked to proceedings that began in 2025.

The update represents another milestone following the Court’s October 2025 judgment in favour of Mayne Pharma and may have contributed to the share price gain recorded on 5 June 2026. However, the legal matter remains active, with Cosette’s appeal having recently been heard and a decision still pending.

Investors will likely continue monitoring future updates regarding the appeal outcome, while also assessing the broader implications of the recovered funds and the company’s ongoing operations.